HC Wainwright restated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research report sent to investors on Friday morning, Briefing.com Automated Import reports. The brokerage currently has a $41.00 price objective on the stock, down from their previous price objective of $45.00.
Separately, William Blair reissued a buy rating on shares of Autolus Therapeutics in a report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. Autolus Therapeutics currently has an average rating of Buy and a consensus target price of $42.67.
Autolus Therapeutics stock opened at $22.59 on Friday. Autolus Therapeutics has a 52-week low of $19.17 and a 52-week high of $53.24. The firm has a market cap of $906.90 million and a PE ratio of -15.91. The company has a quick ratio of 15.14, a current ratio of 10.66 and a debt-to-equity ratio of 0.12.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC purchased a new stake in shares of Autolus Therapeutics in the fourth quarter valued at about $113,000. Virtus ETF Advisers LLC purchased a new stake in shares of Autolus Therapeutics in the fourth quarter valued at about $312,000. Geode Capital Management LLC purchased a new stake in shares of Autolus Therapeutics in the fourth quarter valued at about $322,000. CWM LLC purchased a new stake in shares of Autolus Therapeutics in the first quarter valued at about $1,105,000. Finally, BlackRock Inc. grew its holdings in shares of Autolus Therapeutics by 4,011.3% in the fourth quarter. BlackRock Inc. now owns 202,973 shares of the company’s stock valued at $6,666,000 after purchasing an additional 198,036 shares during the period. 40.63% of the stock is owned by hedge funds and other institutional investors.
Autolus Therapeutics Company Profile
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.
Further Reading: Calculating net profit and net profit margin ratio
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.